Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients.

Humans Multiple Myeloma / drug therapy Cytarabine Etoposide Hematopoietic Stem Cell Mobilization / methods Retrospective Studies Granulocyte Colony-Stimulating Factor Heterocyclic Compounds Lymphoma / drug therapy Antigens, CD34 Transplantation, Autologous
autologous stem cell transplant cytarabine etoposide pegfilgrastim poorly mobilizing

Journal

Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 15 02 2023
revised: 25 04 2023
accepted: 28 04 2023
medline: 3 7 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

An optimal strategy for mobilizing hematopoietic stem cells in poorly mobilizing patients with multiple myeloma (MM) and lymphoma has not yet been determined. We retrospectively analyzed the efficacy and safety of etoposide combined with cytarabine (etoposide 75 mg/m This approach resulted in adequate mobilization (≥2.0 × 10 We conclude that chemo-mobilization with etoposide, Ara-C and pegfilgrastim in poorly mobilizing patients with MM or lymphoma is very effective and has acceptable toxicity.

Sections du résumé

BACKGROUND AIMS OBJECTIVE
An optimal strategy for mobilizing hematopoietic stem cells in poorly mobilizing patients with multiple myeloma (MM) and lymphoma has not yet been determined.
METHODS METHODS
We retrospectively analyzed the efficacy and safety of etoposide combined with cytarabine (etoposide 75 mg/m
RESULTS RESULTS
This approach resulted in adequate mobilization (≥2.0 × 10
CONCLUSIONS CONCLUSIONS
We conclude that chemo-mobilization with etoposide, Ara-C and pegfilgrastim in poorly mobilizing patients with MM or lymphoma is very effective and has acceptable toxicity.

Identifiants

DOI: 10.1016/j.jcyt.2023.04.014 PMID: 37212754
pubmed: 37212754
pii: S1465-3249(23)00130-5
doi: 10.1016/j.jcyt.2023.04.014
pii:
doi:

Substances chimiques

pegfilgrastim 3A58010674
Cytarabine 04079A1RDZ
Etoposide 6PLQ3CP4P3
Granulocyte Colony-Stimulating Factor 143011-72-7
Heterocyclic Compounds 0
Antigens, CD34 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

885-890

Informations de copyright

Copyright © 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.

Auteurs

Peipei Ye (P)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Renzhi Pei (R)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Jiaying Lian (J)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Dong Chen (D)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Shuangyue Li (S)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Yixuan Cheng (Y)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Fenglin Li (F)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Jiaojiao Yuan (J)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Yao Chen (Y)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China.

Ying Lu (Y)

Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China; Institute of Hematology, Ningbo university, Ningbo, Zhejiang, China. Electronic address: rmluying@nbu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Cytarabine › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Glucides › Hétérosides › Glucosides › Étoposide › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Thérapeutique › Biothérapie › Mobilisation de cellules souches hématopoïétiques › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Facteur de stimulation des colonies de granulocytes › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Composés hétérocycliques › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes CD › Antigènes CD34 › Higher efficacy of Etoposide + Cytarabine Plus...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation autologue › Higher efficacy of Etoposide + Cytarabine Plus...